Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01964300 · ClinicalTrials.gov registry record · Phase 2
Peginterferon Alfa-2b in Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery
A Phase 2 study, sponsored by Pediatric Brain Tumor Consortium.
- Terminated
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT01964300 is a Phase 2 study that was terminated before completion, run by Pediatric Brain Tumor Consortium. The registered enrollment target is 19 participants.
The verdict
NCT01964300, a Phase 2 study, was terminated before completion, sponsored by Pediatric Brain Tumor Consortium.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
This phase II trial studies how well peginterferon alfa-2b works in treating younger patients with craniopharyngioma that is recurrent or cannot be removed by surgery. Peginterferon alfa-2b may interfere with the growth of tumor cells and slow the growth of craniopharyngioma.
Interventions
- OTHER laboratory biomarker analysis
- BIOLOGICAL peginterferon alfa-2b
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2014-04-01 |
| Est. Completion | 2019-01-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01964300
The ClinicalTrials.gov registry entry for NCT01964300 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pediatric Brain Tumor Consortium, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT01964300 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01964300 about?
NCT01964300 is a clinical study titled "Peginterferon Alfa-2b in Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery". This phase II trial studies how well peginterferon alfa-2b works in treating younger patients with craniopharyngioma that is recurrent or cannot be removed by surgery. Peginterferon alfa-2b may interfere with the growth of tumor cells and slow the growth of craniopharyngioma.
What is the current status of trial NCT01964300?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2014-04-01. Estimated completion is 2019-01-01.
What interventions are being tested in trial NCT01964300?
The interventions under investigation include: laboratory biomarker analysis (OTHER), peginterferon alfa-2b (BIOLOGICAL).
Who is sponsoring clinical trial NCT01964300?
This trial is sponsored by Pediatric Brain Tumor Consortium, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.